Novo Nordisk A/S
CSE:NOVO B

Watchlist Manager
Novo Nordisk A/S Logo
Novo Nordisk A/S
CSE:NOVO B
Watchlist
Price: 321.15 DKK 0.45% Market Closed
Market Cap: 1.4T DKK

P/E
Price to Earnings

13.7
Current
34.9
Median
21.6
Industry
Lower than median
Lower than industry value

The Price to Earnings (P/E) ratio shows how much investors are willing to pay for each dollar of a company’s earnings. It’s calculated by dividing the company’s market value by its net income.

P/E
13.7
=
Market Cap
1.4T DKK
/
Net Income
103.8B DKK
All Countries
Close
Earnings Growth PEG
DK
Novo Nordisk A/S
CSE:NOVO B
Average P/E: 21.8
13.7
4%
3.4
US
Eli Lilly and Co
NYSE:LLY
52.8
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20.3
29%
0.7
CH
Roche Holding AG
SIX:ROG
26.8
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
29.7
38%
0.8
CH
Novartis AG
SIX:NOVN
17.7
17%
1
US
Merck & Co Inc
NYSE:MRK
13.1
15%
0.9
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -71.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
15
29%
0.5
FR
Sanofi SA
PAR:SAN
7.3
26%
0.3

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
13.5
2-Years Forward
P/E
13.4
3-Years Forward
P/E
12.5